Illustrative image – not actual.Cipla, has entered into a joint venture agreement with Biopharm SPA to form a company in Algeria. The JV company will manufacture and market respiratory products facilitating Cipla's front-end presence in Algeria.
According to the agreement, Cipla (EU), a wholly owned subsidiary of Cipla, will hold a 40 per cent stake in the JV company and the rest will be led by Biopharm-led Algerian consortium.
The JV company is expected to make an investment of up to USD 15 million in the construction of a manufacturing facility. Cipla (EU)’s initial investment in cash in the JV company is expected to be USD six million.
